Table 2 Clinical characteristics according to treatment modality ^a

Age (years)

33.6 ± 18.32

40.06 ± 10.31

0.481

Male/Female {%}

4/1 {80/20}

15/17 {47/53}

<0.0001

Serum Creatinine (mg/dL)

1.52 ± 0.55

1.20 ± 0.69

0.347

CKD EPI eGFR (ml/min/1.73 m²)

70.06 ± 37.03

80.62 ± 29.90

0.505

24 hrs Urinary Protein (mg/day)

4077.18 ± 3098.19

1000.63 ± 899.85

<0.0001

Mean Blood Pressure, systolic (mm/Hg)

128 ± 13

125 ± 14.14

0.693

Mean Blood Pressure, diastolic (mmHg)

76 ± 8.3

78 ± 8.95

0.664

Mesagial hypercellularity (%)

100

59.4

<0.0001

Segmental glomerularsclerosis (%)

100

90.7

<0.0001

Endocapillary hypercellularity (%)

80

31.3

<0.0001

Tubular atrophy/interstitial fibrosis 1 (%)

0

37.5

<0.0001

Tubular atrophy/interstitial fibrosis 2 (%)

60

15.7

<0.0001

Baseline KIM-1/Cr (ng/mg)

0.51 [0.31-1.23]

1.12 [0.62-2.02]

0.155

Follow-up KIM-1/Cr (ng/mg)

0.52 [0.01-0.64]

0.26 [0.13-0.73]

0.625

Δ KIM-1/Cr (ng/mg)

0.49 [0.34-0.71]

0.81 [0.17-1.23]

0.230

Baseline eGFR (ml/min/1.73 m²)

70.65 ± 37.03

80.62 ± 29.9

0.505

Follow-up eGFR (ml/min/1.73 m²)

72.82 ± 48.44^*

82.26 ± 30.03^**

0.552

Baseline proteinuria (mg/d)

4855.1 [1569.7-5560.5]

720 [401-1189.7]

Follow-up proteinuria (mg/d)

1323.9 [374.6-1480]

545.6 [250.5-824]

P

0.273

0.077